Business
Appointment of Stewart Williams as Consultant
Physiomics plc has appointed Stewart Williams as a consultant to support the senior leadership transition and execute its growth strategy, leveraging his over 30 years of experience in complex transformation programs across life sciences and regulated sectors, including senior roles at PwC and KPMG and leadership positions at major companies like AstraZeneca. The company continues to experience steady commercial activity with contract awards and program renewals, aligning with its strategy of building long-term client engagements. Disclaimer*
About this update from Physiomics Plc
12 May 2026 Physiomics plc ("Physiomics" or the "Company") Appointment of Stewart Williams as Consultant Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the appointment of Stewart Williams FCILT as a consultant to the Company. Mr Williams will support the Board and management team during the Company's senior leadership transition, providing strategic, operational and programme delivery expertise to assist with the ongoing development and execution of the Company's growth strategy. Mr Williams brings more than 30 years of experience advising and leading complex transformation programmes across life sciences and other regulated sectors. His background includes senior consulting roles with PwC and KPMG, alongside leadership positions delivering large-scale operational and digital transformation programmes for organisations including AstraZeneca, Victrex, BAE Systems and Co-operative Financial Services. He currently serves as Head of Planning for AstraZeneca's c. $2 billion AXIAL transformation programme. The Board believes Stewart's extensive expertise in governance, operational delivery, programme management and strategic execution will provide valuable support as Physiomics continues to advance its commercial and operational objectives. The Company continues to see steady levels of commercial activity across both new and existing client relationships, including a combination of contract awards and ongoing programme renewals. This reflects the Board's expectations for continued operational progress and supports the Company's broader strategy of building long-term, recurring client engagements. Stewart Williams commented: "I am pleased to be working with Physiomics and the new Board at an important stage in the Company's development. Physiomics has built strong scientific and technical capabilities, and I look forward to supporting the leadership team through this transition period. My focus will be on helping the Company execute efficiently, strengthen operational delivery and, where possible, help expedite key projects and strategic initiatives." Executive Director Mike Whitlow commented: "We are delighted to welcome Stewart to Physiomics. His depth of experience across transformation leadership, governance and operational delivery within highly regulated environments will be of considerable value to the Company as we continue to strengthen the business and execute on our strategic priorities." ENDS For more information about Physiomics and its services, please visit www.physiomics.co.uk . Enquiries: Physiomics plc Mike Whitlow Email: [email protected] Strand Hanson Ltd (NOMAD) James Dance & James Bellman Tel: + 44 (0)20 7409 3494 Hybridan LLP (Broker) Claire Louise Noyce Tel: +44 (0) 203 764 2341 About Physiomics Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.